Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kaohsiung J Med Sci. 2017 Aug;33(8):394-399. doi: 10.1016/j.kjms.2017.05.017. Epub 2017 Jul 1.
Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) has recently been developed as a promising liver fibrosis glyco biomarker. We assessed its efficacy in evaluating liver disease severity in chronic hepatitis C (CHC) in Taiwan. The association between WFA-M2BP and histological features was evaluated among those CHC patients underwent liver biopsy. We also aimed to clarify the factors determining the performance of WFA-M2BP in CHC. A total of 229 CHC patients were consecutively recruited. The mean value of WFA-M2BP in patients from F0 to F4 was 1.68, 2.23, 3.45, 3.48, 3.77 respectively (linear trend P = 0.008). Linear regression analysis revealed that alanine aminotransferase (odds ratio [OR]: 0.03, 95% confidence intervals [CI]: 0.02-0.05, P < 0.001), AST (OR: -0.1, 95% CI: -0.02 to -0.01, P < 0.001), and liver fibrosis (OR: 0.30, 95% CI: 0.01-0.59, P = 0.043) were the independent factors correlated to serum WFA-M2BP level. The optimal cutoff values of WFA-M2BP for fibrosis stages F1, F2, F3, and F4 were 1.42, 1.61, 1.42, and 2.67, respectively. Multivariate analysis revealed that the platelet count (OR/CI: -0.009/0.986-0.996, P = <0.001), r-glutamyl transferase (OR/CI: 0.007/1.000-1.013, P = 0.036), and WFA-M2BP (OR/CI: 0.187/1.057-1.374, P = 0.005). We concluded that WFA-M2BP is a competent noninvasive marker for liver fibrosis assessment in CHC patients.
近期研发的 紫藤凝集素阳性 Mac-2 结合蛋白（WFA-M2BP）有望成为一种新型肝纤维化糖基生物标志物。本研究旨在评估其在台湾地区慢性丙型肝炎（CHC）患者中的应用价值。对接受肝活检的 CHC 患者进行研究，评估 WFA-M2BP 与组织学特征的相关性，并明确影响 WFA-M2BP 性能的因素。共连续纳入 229 例 CHC 患者。F0 至 F4 期患者的 WFA-M2BP 平均值分别为 1.68、2.23、3.45、3.48、3.77（线性趋势 P = 0.008）。线性回归分析显示，丙氨酸氨基转移酶（比值比 [OR]：0.03，95%置信区间 [CI]：0.02-0.05，P < 0.001）、天冬氨酸氨基转移酶（OR：-0.1，95% CI：-0.02 至 -0.01，P < 0.001）和肝纤维化（OR：0.30，95% CI：0.01-0.59，P = 0.043）是与血清 WFA-M2BP 水平相关的独立因素。WFA-M2BP 用于纤维化分期 F1、F2、F3 和 F4 的最佳截断值分别为 1.42、1.61、1.42 和 2.67。多变量分析显示，血小板计数（OR/CI：-0.009/0.986-0.996，P < 0.001）、γ-谷氨酰转移酶（OR/CI：0.007/1.000-1.013，P = 0.036）和 WFA-M2BP（OR/CI：0.187/1.057-1.374，P = 0.005）。综上，WFA-M2BP 是评估 CHC 患者肝纤维化的一种有效的非侵入性标志物。
